Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rome – page 115

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 209
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 209 trials in Rome

Open in trial search

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Back pain

Not recruiting

Study on the Effectiveness of Diclofenac Sodium and Thiocolchicoside in Relieving Acute Low Back Pain in Adults

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac
  • Sponsor:Epifarma S.r.l.

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Paget's disease of the vulva

Not recruiting

Study on Electrochemotherapy with Bleomycin and Cisplatin for Treating Vulvar Paget's Disease and Precancerous Lesions in Newly Diagnosed or Recurrent Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Ovarian cancer

Not recruiting

Study on Doxorubicin Hydrochloride and Trabectedin for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trabectedin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

  • Pulmonary function assessment
  • Disease exacerbation prevention
  • RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

  • Targeted molecular therapies
  • Combination treatment approaches
  • Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

  • Early disease intervention
  • Stroke treatment optimization
  • Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

  • Immune system modulation
  • Novel biological therapies
  • Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.